Interpretation of the evidence for the efficacy and safety of statin therapy.

By R. Collins, C. Reith, J. Emberson, J. Armitage, C. Baigent, L. Blackwell, R. Blumenthal, John Danesh, George Davey Smith, D. DeMets and 18 more. The Lancet, 2016

1,672 citations recorded by the source corpus.

Subfields: Cancer Research, Economics and Econometrics, Surgery

View Paper: https://www.semanticscholar.org/paper/3196caba44dab06d8803967fa53d0233f7e50024

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Economics and Econometrics

In Surgery

Citations in the corpus

Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. (2017, background): “The degree of reduction in CVD is proportionate to the degree of lowering of LDL cholesterol, and it is estimated that a 1-mmol reduction in LDL cholesterol in middle-aged individuals for 5 years leads to a 20% reduction in CVD risk.(38) In 2008, the worldwide age-standardized mean total cholesterol”
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis (2020, background): “Multiple large-scale randomised trials of lipid-modifying therapies have conclusively shown that lowering of cholesterol in atherogenic lipoproteins leads to a reduction in risk of CHD [4,5].”
Biomarker definitions and their applications (2018, neutral): “However, in multiple clinical trials cumulatively enrolling more than 100,000 patients, the relative effect on event reduction is similar across all levels of LDL cholesterol, including levels well within the normal range.(13) Therefore, in clinical trials, the event reduction is a function of the o”
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017, background): “The magnitude of this effect was independent of baseline LDL-C level, similar among persons with and without preexisting cardiovascular disease at baseline, and remarkably consistent in all subgroups studied.(32,33) This meta-analysis therefore provides powerful evidence that reducing plasma LDL-C l”
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Effective interventions to prevent ASCVD, including statins, typically exhibit similar relative risk reductions across categories of patients, including by ASCVD risk; therefore, health benefits and cost-effectiveness are greater among people at higher ASCVD risk (Figure 6).(36,233) Consequently, in”
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, methodology): “For evaluation of the tolerability and safety of a medication, the quality of evidence provided by placebo-controlled trials is recognized as superior to evidence from pharmacoepidemiologic studies.(17,19) Nevertheless, various criticisms have been raised, and addressed,(19,70) regarding statin RCTs”